Date: 11/03/2025

Author Marie Bosslett, Assistant Editor

These data provide the clearest clinical evidence to date that the active ingredient in QRX003 is a competitive broad-spectrum serine protease inhibitor. The rapid reversal of benefit upon discontinuation highlights the critical need for chronic whole-body treatment. Read more here https://www.dermatologytimes.com/view/icymi-quoin-s-qrx003-receives-fda-orphan-drug-status-for-netherton-syndrome/?ekey=RUtJRDpCNzMwQUMzMS02NDZBLTQ3Q0QtQjc3Qy03Q0NFMjE4QzdEQjY%3D&_hsenc=p2ANqtz--x7JbeXoT5VXkBxVKFhkG7nGbbsjdjkr3Qyv8hUMji9xucyHWGrJI6GxwIawgaenb571csx6eppTjUFcaSgzSUrBxV9A-EEIO33GxUnfdUlyFSydc&_hsmi=387818859